Genomic instability is a defining hallmark of cancer, underpinning tumor initiation, evolution, and progression. Increasingly, genomic instability itself is recognized not merely as a consequence of ...
Even as therapies improve, a startling number of cancer patients are not getting genomic tests that could improve their chance of survival.
Hiroshima University researchers have developed a practical framework to identify candidate pathogenic variants hidden among ...
There exists a complex synergistic relationship among cancer, circadian rhythms, and aging: aging is a major risk factor for cancer, disruption of circadian rhythms promotes tumor initiation and ...
Genetic testing identifies germline mutations, while genomic testing analyzes somatic mutations in tumors, influencing treatment options. Broader testing criteria are expanding access to genetic ...
Accent Therapeutics, a clinical-stage biopharmaceutical company pioneering novel small molecule precision cancer therapies, ...
Hosted on MSN
Landscape of KRAS mutations and targeted therapies in colorectal cancer mapped in new study
A team of researchers from the Germans Trias i Pujol Research Institute (IGTP) and Institut Català d'Oncologia (ICO) has studied alterations in the KRAS gene in colorectal cancer by combining genomic ...
Autologous T-Cell Therapies in Solid Tumor Malignancies: Current Landscape and Future Opportunities Histology-agnostic therapies: by focusing on common mutations across various cancers, this approach ...
A new study shows that cancer damages its own DNA by pushing key genes to work too hard. Researchers found that the most powerful genetic "on switches" in cancer cells, called super-enhancers, drive ...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results